BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31160355)

  • 1. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
    Williamson LM; Steel M; Grewal JK; Thibodeau ML; Zhao EY; Loree JM; Yang KC; Gorski SM; Mungall AJ; Mungall KL; Moore RA; Marra MA; Laskin J; Renouf DJ; Schaeffer DF; Jones SJM
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
    Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
    Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
    Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
    Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
    Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
    Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
    Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
    Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
    Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
    Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
    Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Navale P; Chatterjee D; Itani M; Trikalinos NA
    Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
    Singhi AD; Liu TC; Roncaioli JL; Cao D; Zeh HJ; Zureikat AH; Tsung A; Marsh JW; Lee KK; Hogg ME; Bahary N; Brand RE; McGrath KM; Slivka A; Cressman KL; Fuhrer K; O'Sullivan RJ
    Clin Cancer Res; 2017 Jan; 23(2):600-609. PubMed ID: 27407094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
    Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
    Arakelyan J; Zohrabyan D; Philip PA
    Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
    Jiang R; Hong X; Zhao Y; Wu W
    Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.
    Pea A; Yu J; Marchionni L; Noe M; Luchini C; Pulvirenti A; de Wilde RF; Brosens LA; Rezaee N; Javed A; Chianchiano P; Gobbo S; Regi P; Salvia R; Bassi C; He J; Weiss MJ; Cameron JL; Offerhaus GJA; Hruban RH; Lawlor RT; Scarpa A; Heaphy CM; Wood LD; Wolfgang CL
    Ann Surg; 2020 Mar; 271(3):566-573. PubMed ID: 30339629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification.
    Khanna L; Prasad SR; Sunnapwar A; Kondapaneni S; Dasyam A; Tammisetti VS; Salman U; Nazarullah A; Katabathina VS
    Radiographics; 2020; 40(5):1240-1262. PubMed ID: 32795239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.